282 related articles for article (PubMed ID: 36984544)
1. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A; Cainap SS; Havasi AT; Cainap C
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984544
[TBL] [Abstract][Full Text] [Related]
2. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
[TBL] [Abstract][Full Text] [Related]
3. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer.
Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
[TBL] [Abstract][Full Text] [Related]
4. Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
Gambelli A; Nespolo A; Rampioni Vinciguerra GL; Pivetta E; Pellarin I; Nicoloso MS; Scapin C; Stefanatti L; Segatto I; Favero A; D'Andrea S; Mucignat MT; Bartoletti M; Lucia E; Schiappacassi M; Spessotto P; Canzonieri V; Giorda G; Puglisi F; Vecchione A; Belletti B; Sonego M; Baldassarre G
EMBO Mol Med; 2024 May; 16(5):1162-1192. PubMed ID: 38658801
[TBL] [Abstract][Full Text] [Related]
5. Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.
Zhang L; Zhang X; Fan S; Zhang Z
Medicine (Baltimore); 2019 Nov; 98(44):e17803. PubMed ID: 31689861
[TBL] [Abstract][Full Text] [Related]
6. Iron promotes ovarian cancer malignancy and advances platinum resistance by enhancing DNA repair via FTH1/FTL/POLQ/RAD51 axis.
Zhang Q; Chen C; Zou X; Wu W; Di Y; Li N; Fu A
Cell Death Dis; 2024 May; 15(5):329. PubMed ID: 38740757
[TBL] [Abstract][Full Text] [Related]
7. Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance.
Kapper C; Oppelt P; Arbeithuber B; Gyunesh AA; Vilusic I; Stelzl P; Rezk-Füreder M
Life Sci; 2024 Jul; 349():122720. PubMed ID: 38762066
[TBL] [Abstract][Full Text] [Related]
8. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.
Ghoneum A; Almousa S; Warren B; Abdulfattah AY; Shu J; Abouelfadl H; Gonzalez D; Livingston C; Said N
Semin Cancer Biol; 2021 Dec; 77():83-98. PubMed ID: 33476723
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.
Nunes M; Bartosch C; Abreu MH; Richardson A; Almeida R; Ricardo S
Cells; 2024 May; 13(9):. PubMed ID: 38727322
[TBL] [Abstract][Full Text] [Related]
10. New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings.
El Bairi K; Madariaga A; Trapani D; Al Jarroudi O; Afqir S
Int J Gynecol Cancer; 2024 May; 34(5):760-772. PubMed ID: 38101815
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Pathways and Targeted Therapies in Ovarian Cancer.
Lliberos C; Richardson G; Papa A
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785992
[TBL] [Abstract][Full Text] [Related]
12. Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer.
Sidaway P
Nat Rev Clin Oncol; 2024 Feb; 21(2):83. PubMed ID: 38114788
[No Abstract] [Full Text] [Related]
13. Clinical and translational advances in ovarian cancer therapy.
Konstantinopoulos PA; Matulonis UA
Nat Cancer; 2023 Sep; 4(9):1239-1257. PubMed ID: 37653142
[TBL] [Abstract][Full Text] [Related]
14. ASO Author Reflections: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Platinum-Resistance Ovarian Cancer Patients.
Vizzielli G; Giudice MT; Fagotti A; Scambia G
Ann Surg Oncol; 2024 Feb; 31(2):1217-1218. PubMed ID: 38071702
[No Abstract] [Full Text] [Related]
15. Investigating the mechanisms of drug resistance and prognosis in ovarian cancer using single-cell RNA sequencing and bulk RNA sequencing.
Liu P; Liu J; Liu J; Yu X
Aging (Albany NY); 2024 Mar; 16(5):4736-4758. PubMed ID: 38461424
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview.
Baglini E; Chiaverini L; Tolbatov I; Taliani S; Da Settimo F; La Mendola D; Barresi E; Marzo T
Biometals; 2024 Apr; 37(2):275-288. PubMed ID: 37930483
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the novel immune and molecular signatures of ovarian cancer: insights and innovations from single-cell sequencing.
Li Z; Gu H; Xu X; Tian Y; Huang X; Du Y
Front Immunol; 2023; 14():1288027. PubMed ID: 38022625
[TBL] [Abstract][Full Text] [Related]
18. Transforming ovarian cancer care by targeting minimal residual disease.
Jazaeri AA; Grisham R; Knisely A; Spranger S; Zamarin D; Hillman RT; Lawson BC; Burns KH; Lee S; Westin SN; Moiso E; Williams MJ; Bardhan NM; Pisanic T; Matulonis U; Weigelt B; Shih I; Konstantinopoulos PA; Gaillard S; Wang L; Aghajanian C; D'Andrea AD; Hammond P; Shah S; Wucherpfennig KW; Lu KH
Med; 2023 Nov; 4(11):755-760. PubMed ID: 37951209
[TBL] [Abstract][Full Text] [Related]
19. Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase.
Grossi V; Simone C
J Oncol; 2012; 2012():382159. PubMed ID: 22481926
[TBL] [Abstract][Full Text] [Related]
20. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL; Eskander RN; O'Malley DM
JAMA Oncol; 2023 Jun; 9(6):851-859. PubMed ID: 37079311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
